Rahlfs Capital’s Pfizer PFE Stock Holding History

Rahlfs Capital’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$907K	Hold	37,686	–	–	0.67%	40
2026 Q1	$1.06M	Hold	37,686	–	–	0.78%	41
2025 Q4	$938K	Sell	37,686 -867	-2%	-$21.9K	0.73%	38
2025 Q3	$982K	Sell	38,553 -800	-2%	-$19.7K	0.78%	40
2025 Q2	$954K	Buy	39,353 +900	+2%	+$21K	0.87%	37
2025 Q1	$974K	Sell	38,453 -1,500	-4%	-$39.3K	0.98%	34
2024 Q4	$1.06M	Buy	+39,953	New	+$1.08M	1.05%	28

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Rahlfs Capital's PFE Position: Q2 2026 in Review

Rahlfs Capital held its Pfizer (PFE) position steady in Q2 2026 at 37,686 shares worth $907K. The position accounts for 0.67% of the portfolio, ranked #40.

Rahlfs Capital first reported a position in PFE in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.06M in Q4 2024. 2,831 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

Rahlfs Capital held 37,686 shares of Pfizer worth $907K as of Q2 2026.
Rahlfs Capital left its Pfizer share count unchanged in Q2 2026.
Pfizer made up 0.67% of Rahlfs Capital's portfolio in Q2 2026, its #40 holding.
Rahlfs Capital first reported a position in Pfizer in Q4 2024 and has held it in 7 quarters since.
Rahlfs Capital's Pfizer position peaked at $1.06M in Q4 2024.
2,831 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Rahlfs Capital's 13F filing for Q2 2026, filed 28 Jul 2026.